Revised Un-audited Financial Result for 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bacil Pharma reported unaudited results for the quarter ended December 2025. The company has zero revenue from operations; all income is classified as 'other income,' which stood at ₹6.45 lakh in Q3 FY26 versus ₹0.30 lakh in Q3 FY25. For the nine months ended December 2025, total income rose to ₹112.19 lakh from ₹57.40 lakh a year ago, nearly doubling. Profit after tax for the nine months jumped to ₹72.17 lakh from ₹38.81 lakh (around 86% growth), while Q3 swung to a ₹3.92 lakh profit from a ₹6.20 lakh loss in the year-ago quarter. The statutory auditor issued an unmodified review opinion but flagged an emphasis of matter noting the company did not raise funds through share allotments during the year and that TDS return filing compliance was pending.
The company remains operationally inactive, with profitability driven entirely by other income rather than core business, making earnings quality weak. Positive profit growth and a swing to quarterly profit are marginally supportive, but the lack of operating revenue limits fundamental value for shareholders.